Impact of Long-Term Intravitreal Anti-VEGF Injections on Cataract Progression and Surgical Outcomes
Introduction
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents have become the gold standard for treating various retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). While these therapies are highly effective in preserving and improving visual acuity, their long-term safety profile regarding the anterior segment remains a subject of investigation. This report analyzes the clinical impact of chronic anti-VEGF administration on the development and progression of cataracts leading to surgical intervention.
Patient Information
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.